NASDAQ: ANIK

Anika Therapeutics Inc Stock Forecast, Predictions & Price Target

The consensus among 2 Wall Street analysts covering (NASDAQ: ANIK) stock is to Buy ANIK stock.

Out of 2 analysts, 0 (0%) are recommending ANIK as a Strong Buy, 1 (50%) are recommending ANIK as a Buy, 1 (50%) are recommending ANIK as a Hold, 0 (0%) are recommending ANIK as a Sell, and 0 (0%) are recommending ANIK as a Strong Sell.

If you're new to stock investing, here's how to buy Anika Therapeutics stock.

(NASDAQ: ANIK) Anika Therapeutics's forecast annual revenue growth rate of 3.95% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.7%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.39%.

Anika Therapeutics's revenue in 2024 is $166,662,000.On average, 1 Wall Street analysts forecast ANIK's revenue for 2024 to be $2,521,757,751, with the lowest ANIK revenue forecast at $2,521,757,751, and the highest ANIK revenue forecast at $2,521,757,751. On average, 1 Wall Street analysts forecast ANIK's revenue for 2025 to be $2,660,827,458, with the lowest ANIK revenue forecast at $2,660,827,458, and the highest ANIK revenue forecast at $2,660,827,458.

In 2026, ANIK is forecast to generate $2,841,016,654 in revenue, with the lowest revenue forecast at $2,841,016,654 and the highest revenue forecast at $2,841,016,654.

According to 2 Wall Street analysts that have issued a 1 year ANIK price target, the average ANIK price target is $29.50, with the highest ANIK stock price forecast at $37.00 and the lowest ANIK stock price forecast at $22.00.

On average, Wall Street analysts predict that Anika Therapeutics's share price could reach $29.50 by Mar 14, 2025. The average Anika Therapeutics stock price prediction forecasts a potential upside of 16% from the current ANIK share price of $25.43.

(NASDAQ: ANIK) forecast ROE is N/A, which is considered weak.